Brazikumab
| Brazikumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1610353-18-8 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D10912 |
Brazikumab (MEDI2070) (INN) is a human monoclonal antibody designed for the treatment of Crohn's disease.<ref>Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association.</ref><ref>World Health Organization,
International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115, WHO Drug Information, 2016, Vol. 30(Issue: 2), Full text,</ref>
This drug was developed by MedImmune.
References[edit]
<references/>
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page. |
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
